Mortality in patients with HIV-1 and tuberculosis co-infection in Rio de Janeiro, Brazil - associated factors and causes of death

Table 4 Crude and Adjusted HR and 95% CI as estimated by Cox proportional hazards regression for death, n = 310, INI-Fiocruz cohort, 2000–2010

Variable	Crude HR (CI 95%)	p value	Adjusted HR (CI 95%)	p value
Sex
Male	Ref.
Female	1.54 (0.84–2.80)	0.16
Education
Up to 4 years	Ref.
5–8 years	0.75 (0.41–1.35)	0.33
> 8 years	1.26 (0.64–2.48)	0.50
Age at TB diagnosis	1.03 (0.99–1.06)	0.08	1.03 (1.00–1,05)	0.09
Race
White	Ref.
Black	1.21 (0.59–2.49)	0.61	2.03 (0.87–4.78)	0.10
Mixed Black	1.22 (0.69–2.16)	0.49	1.68 (0.89–3.16)	0.11
CD4 T cell count at TB diagnosis (cells\mm³)
> 50	Ref.
≤ 50	2.31 (1.37–3.88)	0.00	3.10 (1.72–5.58)	0.00
Number of ARV change for toxicity	2.12 (0.47–9.55)	0.33
Clinical presentationof TB
Extrapulmonary, localized	Ref.
Disseminated	2.60 (0.97–6.97)	0.06	3.70 (1.29–10.59)	0.01
Pulmonary	1.51 (0.50–5.57)	0.46	2.42 (0.72–8.15)	0.15
Rifampin discontinuation before the end of TB treatment	1.72 (0.83–3.56)	0.15
Mechanical ventilation (n; %)	2.91 (1.36–6.22)	0.01	2.81 (1.17–6.76)	0.02
MTB-IRIS	0.77 (0.37–1.57)	0.47

HR hazard ratio, 95%CI 95% confidence interval;
TB tuberculosis;
ARV antiretroviral;
MTB-IRIS Mycobacteryum tuberculosis related immune reconstitution inflammatory syndrome

ISSN: 1471-2334